Hasija Amit 4/A

What Happened

• Amit Hasija, Chief Financial Officer and EVP of Corporate Development at Milestone Pharmaceuticals (MIST), was reported as acquiring a derivative award of 204,000 shares on February 2, 2026. The filing shows an acquisition price of $0.00 (reported value $0). This is an award/option grant (derivative security), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-02; Amendment filed: 2026-02-05 (this is an amended Form 4).
• Reported transaction: 204,000 derivative shares acquired at $0.00.
• Shares owned after transaction: Not stated in the amended filing.
• Footnote F1: The amendment corrects an incorrectly stated exercise price in the initial filing.
• Footnote F2: Vesting schedule — 1/4 of the option vests on Feb 2, 2027, then 1/36 of the remaining shares vest each month thereafter, subject to continued service.
• No sale or cashless exercise reported; the award is subject to vesting and not immediately liquidated.

Context

• This is a derivative award (option grant) subject to a multi-year vesting schedule; such awards typically tie compensation to future service and company performance. Because the award vests over time, it does not represent immediately tradable shares. The filing is an amendment to correct prior disclosure details (exercise-price information).